Visibility for Bionano Genomics’ OGM The tr
Post# of 93
(Total Views: 41)
Posted On: 09/03/2025 8:29:33 AM
Visibility for Bionano Genomics’ OGM
The train is leaving the station…All aboard!
The decision by the National Institutes of Health Clinical Center to buy Bionano Genomics instruments and test chemicals for optical genome mapping is a major endorsement. This move means the leading U.S. medical research hospital trusts Bionano’s technology as the only source for mapping large DNA changes that other methods often miss. Even though the dollar amount is not public yet, the reputational boost alone can drive interest from investors and research centers.
The Clinical Center is the world’s largest hospital devoted entirely to clinical research. Scientists and doctors there run cutting-edge studies that move laboratory discoveries into patient care. When they adopt a new tool, other hospitals and research groups take notice and follow their lead.
For investors, this partnership signals peer-endorsed technology and a clear path from research to clinical use. The Clinical Center’s choice shows that Bionano’s mapping approach is ready for real-world applications and can become part of funded studies nationwide. As more grants and publications cite optical genome mapping, Bionano stands to gain long-term sales and broader adoption.
The train is leaving the station…All aboard!
The decision by the National Institutes of Health Clinical Center to buy Bionano Genomics instruments and test chemicals for optical genome mapping is a major endorsement. This move means the leading U.S. medical research hospital trusts Bionano’s technology as the only source for mapping large DNA changes that other methods often miss. Even though the dollar amount is not public yet, the reputational boost alone can drive interest from investors and research centers.
The Clinical Center is the world’s largest hospital devoted entirely to clinical research. Scientists and doctors there run cutting-edge studies that move laboratory discoveries into patient care. When they adopt a new tool, other hospitals and research groups take notice and follow their lead.
For investors, this partnership signals peer-endorsed technology and a clear path from research to clinical use. The Clinical Center’s choice shows that Bionano’s mapping approach is ready for real-world applications and can become part of funded studies nationwide. As more grants and publications cite optical genome mapping, Bionano stands to gain long-term sales and broader adoption.
(0)
(0)